Brean Murray Carret & Co. Assumes Coverage on Onyx Pharmaceuticals (ONXX) at Hold
Tweet
Share
E-mailGet Alerts ONXX Hot Sheet
Price: $124.70 --0%
Rating Summary:
9 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
9 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Brean Murray Carret & Co. assumes coverage on Onyx Pharmaceuticals (NASDAQ: ONXX) with a Hold. PT $30.00.
Brean analyst says, "We view the majority of Onyx's value to be based on the indications for Nexavar of HCC and thyroid cancer, and carfilzomib. We project Nexavar to reach $2 billion in sales in 2015, or approximately $580 million in revenue to Onyx."
For more ratings news on Onyx Pharmaceuticals click here and for the rating history of Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $33.69 yesterday.
Brean analyst says, "We view the majority of Onyx's value to be based on the indications for Nexavar of HCC and thyroid cancer, and carfilzomib. We project Nexavar to reach $2 billion in sales in 2015, or approximately $580 million in revenue to Onyx."
For more ratings news on Onyx Pharmaceuticals click here and for the rating history of Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $33.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Canaccord Starts Sunshine Silver Mining & Refining (SSMR) at Spec. Buy
- Goldman Sachs Starts Luxshare Precision (2475:HK) at Buy
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Brean Murray Carret & Co.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
